Research
Hormonal
Visceral fat and epicardial fat are primary drivers of cardiovascular disease pathology through inflammatory and vasocrine signaling, whereas subcutaneous lower-body fat may be protective.
Focus on reducing belly fat (visceral fat) rather than just total weight. Measure your waist circumference. If it is high, prioritize lifestyle changes that target visceral fat, as this specific fat drives heart disease through inflammation.
GoodSupportsHIGH confidence
Among these, visceral fat (estimated from waist circumference) is considered the prime culprit. It incites the synthesis of adipokines and various cytokines... On the contrary, excess accumulation of fat in the lower body (hips and thighs) may actually reduce the chances of developing CVD or diabetes.
Why this rating
Supported by Framingham and MESA studies cited.
Source
Cardiac Diseases and Obesity
Sanjeev Kathuria et al. · Journal of Postgraduate Medicine Education and Research · 2021
DOI 10.5005/jp-journals-10028-1423
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Increased lean mass and cardiorespiratory fitness (CRF) mitigate cardiovascular risk in obese individuals, explaining the 'obesity paradox' where overweight patients with established heart failure have better survival rates than normal-weight counterparts.Good
- Pharmacological weight loss drugs (except specific diabetes drugs like empagliflozin and semaglutide) have not demonstrated improved cardiovascular outcomes or efficacy in reducing visceral/ectopic fat.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →